MN gene and protein
Herein disclosed is a novel oncogene named MN or alternatively MN/CA IX. Abnormal expression of the MN gene is shown to signify oncogenesis, and diagnostic/prognostic methods for pre-neoplastic/neoplastic disease to detect or detect and quantitate such abnormal MN gene expression. Also disclosed are methods to treat pre-neoplastic/neoplastic disease involving the MN gene and protein, e.g., methods comprising the use of MN-specific antibodies, anti-idiotype antibodies thereto, and anti-anti-idiotype antibodies, and the use of MN antisense nucleic acids. Further disclosed are methods to identify and block MN binding site(s) and identify MN protein partners(s).
1 - 23 . (canceled)
24 . An anti-anti-idiotype antibody to an anti-idiotype antibody to a MN-specific antibody, wherein said anti-idiotype antibody comprises an internal image corresponding to an epitope of MN protein, wherein said MN protein has an amino acid sequence of SEQ ID NO: 2 that is encoded by a nucleic acid selected from the group consisting of:
(a) SEQ ID NO: 1; and
(b) polynucleotides that differ from SEQ ID NO: 1 due to the degeneracy of the genetic code.
25 . An anti-anti-idiotype antibody according to claim 24 wherein said MN-specific antibody is either the M75 monoclonal antibody secreted from the hybridoma VU-M75, which was deposited at the American Type Culture Collection under ATCC No. HB 11128, or the MN12 monoclonal antibody that is secreted from the hybridoma MN 12.2.2, which was deposited at the American Type Culture Collection under ATCC No. HB 11647.
26 . An anti-anti-idiotype antibody according to claim 24 which is monoclonal.
27 . An anti-anti-idiotype antibody according to claim 24 which is polyclonal.
28 - 29 . (canceled)
30 . The anti-anti-idiotype antibody according to claim 24 which is recombinantly produced.
31 . The anti-anti-idiotype antibody according to claim 24 which is an antigen-binding antibody fragment.
32 . A method of treating a patient with a preneoplastic and/or neoplastic disease, that is characterized by the abnormal expression of MN protein, by administering to said patient a therapeutically effective amount of an anti-anti-idiotype MN-specific antibody.
33 . The method according to claim 32 , wherein said anti-anti-idiotype antibody is monoclonal.
34 . The method according to claim 32 , wherein said anti-anti-idiotype antibody is polyclonal.
35 . The method according to claim 34 , wherein said polyclonal anti-anti-idiotype antibody is administered in a serum.
36 . The method according to claim 32 further comprising administering to said patient a therapeutically effective amount of one or more cytokines.
37 . The method according to claim 36 wherein said cytokine is either interferon or interleukin-2, or said cytokines are interferon and interleukin-2.